

CURRICULUM VITAE

Name: Mohamed Mohamed Sayed-Ahmed

MAILING ADDRESS: Pharmacology and Experimental Oncology Unit, National Cancer Institute, Kaser El-Aini St., Foum El-Khalig, Cairo, Egypt.
FAX. 002023644720
Home Tel. 002024900159
002024916028
Mobile. 0020101720659
e.mail: mmsayedahmed@hotmail.com

DATE OF BIRTH: 09/03/1962

SEX: Male.

NATIONALITY: Egyptian.

MARITAL STATUS: Married to **Dr. Amira Zakzouk** in 1992. Have Two Children, **Walaa** and **Ahmed** Mohamed Sayed-Ahmed

LANGUAGES: Arabic and English.

EDUCATION:

1980-1985 B. Pharmaceutical SC. **Hon.**, Zagazig Faculty of Pharmacy.

1988-1992 **Master** of Pharmacology and Experimental Oncology, Faculty of Pharmacy, Cairo University. **Thesis: Effect of local Hyperthermia and some Anticancer drugs in the treatment of Solid Ehrlich Carcinoma.**

1992-1995 **Ph.D.** Pharmacology and Experimental Oncology, National Cancer Institute, Cairo University. **Thesis: Pharmacological and Biochemical Studies on the Mechanisms of Adriamycin Induced-Cardiotoxicity.**

EMPLOYMENT RECORDS

- 1988-1992** **Demonstrator** of Pharmacology and Experimental Oncology, Cancer Biology Department, National Cancer Institute, Cairo University.
- 1992-1997** **Assistant Lecturer** of Pharmacology and Experimental Oncology, Cancer Biology Department, National Cancer Institute, Cairo University.
- 1994-1997:** **Ph.D student at Duke University, Medical Center, USA.**
- 1997-2002:** **Lecturer** of Pharmacology and Experimental Oncology, Cancer Biology Department, National Cancer Institute, Cairo University.
- 2002-2007:** **Assistant Professor** of Pharmacology and Experimental Oncology, Cancer Biology Department, National Cancer Institute, Cairo University.
- 2004-present** **Associate Professor** of Pharmacology, Pharmacology Department, College of Pharmacy, King Saud University, Kingdom Saudi Arabia.
- 2007-Present** **Professor** of Pharmacology and Experimental Oncology, Cancer Biology Department, National Cancer Institute, Cairo University.

TEACHING EXPERIENCES

- 1- Teaching experience** in pharmacology and Toxicology for undergraduate students at 6Th of October Faculty of Pharmacy, Cairo, Egypt.

- 2- Teaching experience** in Toxicology, Pharmacology and Experimental Oncology for Postgraduate students, National Cancer Institute, Cairo University.

- 3- Teaching experience** in Pharmacology and Toxicology for Postgraduate students, Faculty of pharmacy, Ain Shams University

- 4- Teaching experience** in Clinical pharmacology and Toxicology for Clinical Pharmacy Students at National Cancer Institute, Cairo University.

- 5- Teaching experience** in Toxicology, Pharmacology and Experimental Oncology for M.D. student, South Egypt Cancer Institute, Assuit University.

- 6- Experience in Teaching Rotation Laboratories** for M.D. and Ph.D. students, National Cancer Institute, Cairo University.

- 7- Teaching experience** in Clinical pharmacology and Toxicology, Pharmacology Department, College of Pharmacy, King Saud University, Kingdom Saudi Arabia.

RESEARCH EXPERIENCES

1- Research Experience in using **L-carnitine** and **Propionyl-L-carnitine** as protective agents against Anticancer drug-induced organs toxicity. (**Duke University, Medical Center, USA**).

2- Research Experience in modulation of Anticancer drugs-induced organ toxicity. (**Duke University, Medical Center, USA**).

3- Research Experience in study the effects of anticancer drugs on cardiac and hepatic metabolism using isotopic dilution technique (**Duke University, Medical Center, USA**).

4- Research Experience in isolation of Cardiac myocytes and liver hepatocytes as toxicity model to study radioactive substrate oxidation in response to anticancer drugs (**Duke University, Medical Center, USA**).

5- Research Experience in modulation of tumour cell drug resistance and in tissue culture Technique dealing with the growth of human tumour cells, tumour cell cycle phase determination using flowcytometry.

6- Good experience in screening the potentially antiangiogenic and antimetastatic agents as biological therapy of cancer and in screening anticancer agents and the interaction between anticancer drugs and other drugs using different tumour cell lines.

7- Good experience in using HPLC technique for determination of plasma level of anticancer drugs, Antibiotics, Narcotics, and L-carnitine as a routine used for the treatment and follow up of Egyptian Cancer Patients. (**Therapeutic drug monitoring**).

List of Publications

- 1- Osman, A. M. ; [Sayed-Ahmed, M. M.](#) ; Khayyal, M. T. and El- Merzabani, M. M.:
Hyperthermic Potentiation of Cisplatin on Solid Ehrlich Carcinoma. **Tumori**
1993, 79: 268-272.
- 2- Shouman, S. A.; [Sayed-Ahmed, M. M.](#) and El-Merzabani, M.M: Potentiation of the
Chemotherapeutic Effect of Methotrexate by Hyperthermia in Experimental
Animal Tumour Model. **J. Egypt. Nat. Cancer Inst. 1994 , 6: 868-876.**
- 3- Abdel-aleem, S. ; Sharawi, S. ; Badr, M. ; [Sayed-Ahmed, M. M.](#) ; Anstadt, M. P. and
Lowe, J.E.: Reduced Induction of Carbohydrate Utilization by Inhibition of
Fatty Acid Oxidation in Myocytes From Diabetic Animals. **Horm. Metab. Res.**
1994, 27: 104-106.
- 4- Abdel-aleem, S. ; [Sayed-Ahmed, M. M.](#); Nada, M. A. ; Hendrickson, S. C. ; Louis, J.
S. and Lowe, J.E.: Stimulation of Non-Oxidative Glucose Utilization by
L-carnitine in Isolated Myocytes. **J. Mol. Cell. Cardiol. 1995, 27: 2465-2472.**
- 5- Abdel-aleem, S. ; [Sayed-Ahmed, M. M.](#); Nada, M. A. ; Hendrickson, S. C. ; Louis, J.
S., Walthall, H.P. and Lowe, J.E.: Regulation of Fatty Acid Oxidation by
Acetyl-CoA Generated From Glucose Utilization in Isolated Myocytes.
J. Mol. Cell. Cardiol. 1996, 28: 825-833.
- 6- Abdel-aleem, S. ; El-Merzabani, M. M. ; [Sayed-Ahmed, M. M.](#) ; Taylor, D. A.
and Lowe, J. E.: Acute and Chronic Effects of Adriamycin on Fatty Acid
Oxidation in Isolated Cardiac Myocytes. **J. Mol. Cell. Cardiol. 1997, 29: 789-**
797.
- 7 - Abidli, N., [Sayed-Ahmed, M.M.](#), El-Gerzawy,S.M.,El-Didi, M.M.
Benlatreche,C.,El-Merzabani,M.M. and Osman,A.M: Verapamil
enhancement of the cytotoxic and cell cycle perturbation of doxorubicin in
Ehrlich ascites carcinoma cells in vivo.

- J. Egyptian National Cancer Institute 1999; 10: 433-438.**
- 8- [Sayed-Ahmed, M.M.](#), Sharawy, S., Shouman, S.A. And Osman, A.M.: Reversal of doxorubicin-induced cardiac metabolic damage by l-carnitine. **Pharmacol. Res. 1999, 39: 289-295.**
- 9- [Sayed-Ahmed, M.M.](#), Khattab, M., Khalifa, A., El-Khabany, M. and Osman, A.M: Potensial promise of using L-carnitine and Coenzyme Q10 as protective agents against Cisplatin-induced nephrotoxicity. **J. Egyptian National Cancer Institute 1999; 11: 167-173.**
- 10- Hanafy M., [Sayed-Ahmed, M.M.](#) and Osman A.M.: The protective effect of methimazole against cisplatin-induced chromosomal aberrations. **Sc. J. Az. Med. Fac.(Girls) 1999, 20: 637-645.**
- 11 - [Sayed-Ahmed M.M.](#), Shouman, S.A., Rezk, B.M., Khalifa, M.H., Osman, A.M. and El-Merzabani, M.M: Propionyl-L-carnitine as potential protective agent against adriamycin-induced impairment of fatty acid beta-oxidation in isolated heart mitochondria. **Pharmacol. Res. 2000, 41: 143-150.**
- 12- Salman T.M. and [Sayed-Ahmed M.M.](#): Effects of trichloroactate, water chlorination by-product, on liver peroxisomes and antioxidant status in rats and mice. **Sc. J. Az. Med. Fac.(Girls) 2000, 21: 631-648.**
- 13- Osman, A.M. Mohamed M.A., Abdel-Wahab A.A., and [Sayed-Ahmed M.M.](#) Modulation by verapamil of doxorubicin induced expression of multidrug resistance gene (MDR-1 P-glycoprotein) in murine tumour mode. **J. Egyptian Nat. Cancer Inst. 2000; 12: 221-227.**
- 14- [Sayed-Ahmed MM](#), Kishk AM, Soloma S and Abdel-aleem S: Protection by L-carnitine against the inhibition of gene expression of heart fatty acid binding protein by chronic administration of doxorubicin. **J. Egyptian Nat. Cancer**

Inst. 2000, 12: 275-281.

- 15- A.M.Osman, H.Gaballa, N.H.Mohamed,N.M.Ali., [M.M.Sayed-Ahmed](#),and H. M.Arafa : Plasma endothelin(ET-1) as a marker for doxorubicin-induced cardiotoxicity in Egyptian patients. **J.Egypt Soc.Toxicol 2000; 23: 59-64.**
- 16- Ramadan LA, El-Habit O, Arafa H and [Sayed-Ahmed MM](#) : Effect of cremophor-El on cisplatin induced organs toxicity in normal rats.
J. Egyptian Nat. Cancer Inst. 2001, 13: 11-17.
- 17- [Sayed-Ahmed, M.M.](#), Salman T.M., Gaballah, H.E., Abo El-Nagah, S.A., Nicolia, R. and Calvani, M.: Propionyl-L-carnitine as protector against adriamycin-induced cardiomyopathy. **Pharmacol. Res. 2001, 43: 513-520.**
- 18- Ramadan LA, Shouman SA, [Sayed-Ahmed Mmand](#) El-Habit OH :
Modulation of radiation induced organs toxicity by Cremophor-El in experimental animals. **Pharmacol Res 2001, 43: 185-191.**
- 19- [Sayed-Ahmed M.M.](#), Khattab M.M., Gad M.Z. and Osman A.M.: Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy. **Pharmacology & Toxicology 2001, 89: 140-144.**
- 20- [Sayed-Ahmed M.M.](#), Khattab M.M., Gad M.Z. and Mostafa N.: L-carnitine prevents the progression of Atherosclerotic lesions in hypercholesterolemic rabbits. **Pharmacol Res 2001; 44: 235-242.**
- 21- [Sayed-Ahmed M.M.](#), Shouman S.A., and Ramadan L.A.: Contribution of nitric oxide in doxorubicin-related cytotoxicity in murine tumour model.
J Egyptian Nat Cancer Inst 2002; 14: 111-116.
- 22- Arafa H.M. and [Sayed-Ahmed M.M.](#): Protective role of carnitine esters against alcohol-induced gastric lesions in rats.

Pharmacol Res 2003; 48: 285-290.

- 23- El-Demerdash E., Ali A.A., [Sayed-Ahmed M.M.](#) and Osman A.M.: New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity. **Cancer Chemother and Pharmacol 2003; 52: 411-416.**
- 24- [Sayed-Ahmed M.M.](#), Eissa M.A., Kenawy S.A., Mostafa M., Calvani M. and Osman A.M.: Progression of cisplatin-induced nephrotoxicity in carnitine-depleted rat model. **Chemotherapy 2004; 50: 162-170.**
- 25- [Sayed-Ahmed M.M.](#), Mansour H.H., Gharib O.A. and Hafez F.H: Acetyl-L carnitine Modulates bleomycin-induced oxidative stress and energy depletion in lung tissues. **J Egyptian Nat Cancer Inst 2004; 16: 237-243.**
- 26- El-Demerdash E., Awad A.S, Taha R.M, El-Hady A.M., and [Sayed-Ahmed M.M.](#) ProbucoI attenuates oxidative stress and energy decline in isoproterenol-induced congestive heart failure in rat. **Pharmacol Res 2005; 51: 311-318.**
- 27- [Sayed-Ahmed M.M](#) and Mohamed A. M.: Contribution of nitric oxide and epidermal growth factor receptor in antimetastatic potential of paclitaxel in human liver cancer cells (Heb G2). **J Egyptian Nat Cancer Inst 2005; 17: 35-41.**
- 28- Al-Majed A.A., [Sayed-Ahmed M.M.](#), Al-Yahya A.A., Aleisa A.M., Al-Rejaie S.S. Al-Shabanah O.A. Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model. **Pharmacol Res 2006; 53: 278-286.**
- 29- Al-Majed A.A., [Sayed-Ahmed M.M.](#), Al-Omar F.A., Al-Yahya A.A., Aleisa A.M. and Al-Shabanah O.A.: Carnitine esters prevent oxidative stress damage and energy

depletion following transient forebrain ischemia in the rat hippocampus. **Clin Exp Pharmacol Physiol 2006; 33: 725-733.**

30- [Sayed-Ahmed M.M.](#) and Nagi M.N. Thymoquinone supplementation prevents the development of gentamicin-induced acute renal toxicity in rats. **Clin Exp Pharmacol Physiol 2007; 34: 399-405.**

31- Kamel M.W., Salama S.A., Saleh S., Osman A.M., [Sayed-Ahmed M.M.](#), Al-Hendy A. Reversal of doxorubicin resistance by adenovirus-mediated transfer of cyclooxygenase-2 antisense in multidrug-resistant MCF-7 cells. **Cancer Therapy 2007; 5: 1-10.**

32- Aleisa AM, Al-Majed AA, Al-Yahya AA, Al-Rejaie SS, Bakheet SA, Al-Shabanah OA and [Sayed-Ahmed MM](#): Reversal of cisplatin-induced carnitine deficiency and energy starvation by propionyl-l-carnitine in rat kidney tissues. **Clin Exp Pharmacol Physiol 2007; 34: 1252–1259.**

33- [Sayed-Ahmed MM](#): Increased Serum and Cardiac Acyl-carnitine/Free Carnitine ratio During Development of Doxorubicin-Induced Cardiotoxicity. **Saudi Pharmaceutical Journal 2007: 15: 120-126.**

34- [Sayed-Ahmed MM](#): Multidrug resistance to cancer chemotherapy: Genes involved and blockers. **Saudi Pharmaceutical Journal 2007: 15: 161-175.**

35- Al-Rejaie SS, Aleisa AM, Al-Yahya AA, Bakheet SA, Alsheikh A, Fatani AG, Othman A. Al-Shabanah OA and [Sayed-Ahmed MM](#). Carnitine Supplementation Prevents the Progression of Hepatic Carcinogenesis Induced by Diethylnitrosamine in Carnitine-Depleted Rats. **World Journal of Hepatology (2008 in press).**

